Skip to main content
x
About searching

Search results

  1. ESMO 2024 – Bristol abandonment overshadows Immatics

    ESMO 2024 – Bristol abandonment overshadows Immatics …

    - 09/18/2024 - 16:57

  2. ESMO 2024 – Torl challenges BioNTech in Claudin6

    ESMO 2024 – Torl challenges BioNTech in Claudin6 … Cross-trial comparison of Claudin-6-targeted projects at ESMO 2024   BNT211 TORL-1-23 DS-9606a …

    - 09/17/2024 - 12:26

  3. ESMO 2024 – Bristol bucks the degrader trend

    ESMO 2024 – Bristol bucks the degrader trend …

    - 09/17/2024 - 12:26

  4. ESMO 2024 – Astellas defends its degrader

    ESMO 2024 – Astellas defends its degrader …

    - 10/09/2024 - 14:56

  5. ESMO 2024 – Scorpion joins Relay in the alpha club

    ESMO 2024 – Scorpion joins Relay in the alpha club …

    - 09/18/2024 - 21:45

  6. ESMO 2024 – J&J eyes Rybrevant colorectal expansion

    ESMO 2024 – J&J eyes Rybrevant colorectal expansion …

    - 09/16/2024 - 12:28

  7. ESMO 2024 – a role for immunotherapy in ovarian cancer

    ESMO 2024 – a role for immunotherapy in ovarian cancer …

    - 09/15/2024 - 21:18

  8. ESMO 2024 – combos could be the way forward for CDK2

    ESMO 2024 – combos could be the way forward for CDK2 … Pfizer Blueprint Medicines Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 …

    - 09/15/2024 - 21:18

  9. ESMO 2024 – Keytruda/Lenvima leap... up to a point

    ESMO 2024 – Keytruda/Lenvima leap... up to a point …

    - 09/15/2024 - 15:51

  10. ESMO 2024 – Opdualag comes under fire

    ESMO 2024 – Opdualag comes under fire …

    - 09/15/2024 - 08:35